NDA Spotlight

Spotlight Profile: NDA's comments on the new HTA regulation proposed by the EU Commission

A five minute background and introduction to the new proposal for a Health Technology Assessment regulation in Europe. Presented by Johan Strömquist, CEO of NDA Group, the world's leading drug development consultancy.

Spotlight Profile: Dr Lönngren's comments on the relocation of EMA

Dr Thomas Lönngren, Strategic Advisor at NDA Group and former Executive Director at the EMA, gives his comments on the recent decision to relocate the Agency to Amsterdam.

Spotlight Profile: NDA & PharmApprove announces merger

On the 1st March 2016 NDA & PharmApprove announced the merger of the two companies to form one of the world's foremost drug development consultancies.